Oncology Vol 29 No 10

You may have noticed that the issue you received last month looked a little different than what you’re used to seeing from the ONCOLOGY journal!

In this interview we discuss the results of the CLEOPATRA trial, which studied the effect of adding pertuzumab to docetaxel and trastuzumab on HER2-positive metastatic breast cancer.

We will discuss the deleterious cardiovascular effects of anthracyclines and HER2-targeted agents in a case-based format, as well as specific approaches to prevention and treatment of associated cardiotoxicity.

The absence of any effective combinatorial therapy in patients progressing on bevacizumab and evidence supporting both continuation and discontinuation of bevacizumab in this setting remain important areas for additional clinical trial evaluation in order to better guide our therapeutic decision making in the clinic.

While breast-conserving surgery after neoadjuvant chemotherapy has become more accepted over time, methods of management of the axillary lymph nodes have remained matters of controversy.

It is incumbent on melanoma and radiation oncology researchers alike to further our understanding of when and how RT can help patients.

The treatment of patients with follicular lymphoma is undergoing a substantial shift due to rapid development of highly effective agents targeting lymphoma-specific biologic processes and the tumor microenvironment.

The diversity and complexity, combined with the rarity of salivary gland malignancies, lead to definite and distinct challenges in their study, and consequently in advancing treatment options for affected patients.